Paris - Delayed Quote EUR

Carmat SA (ALCAR.PA)

0.8052

+0.0002

+(0.02%)

As of 1:57:39 PM GMT+2. Market Open.

CARMAT: Availability of the 2024 Universal Registration Document

PARIS, April 30, 2025--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announced the publication of the Company’s Universal registration document ("URD") for the year ended December 31, 2024.

Business Wire 5 days ago

ALCAR.PA
+0.02%
CARMAT Announces Its 2024 Annual Results

PARIS, April 29, 2025--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces its annual results for the year ending December 31, 20241.

Business Wire 7 days ago

ALCAR.PA
+0.02%
FDA conditionally approves second cohort of Carmat’s artificial heart study

Carmat is preparing to commence implants in the second half of this year.

Medical Device Network 20 days ago

ALCAR.PA
+0.02%
CARMAT Receives FDA Conditional Approval to Initiate the Second Cohort of the EFS Study in the United States

PARIS, April 14, 2025--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces that it has received conditional approval from the U.S. Food and Drug Administration (FDA) to initiate the second cohort of its Early Feasibility Study (EFS) with Aeson® artificial heart in the United S

Business Wire 21 days ago

ALCAR.PA
+0.02%
CARMAT Delivers Q1 2025 Results in Line With Its Objectives

PARIS, April 09, 2025--Regulatory News: CARMAT (Paris:ALCAR):

Business Wire 26 days ago

ALCAR.PA
+0.02%
CARMAT - Publication in the JACC(1): Heart Failure of the Initial Clinical Experience with Aeson® Total Artificial Heart in Cardiogenic Shock Patients Initially Placed on Extracorporeal Life Support

PARIS, April 03, 2025--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces the publication of the results of the initial clinical experience with Aeson® in cardiogenic shock patients previously on temporary extracorporeal life support2, in the JACC: Heart Failure.

Business Wire last month

ALCAR.PA
+0.02%
CARMAT to Provide a Business Update and Host a Videoconference on April 9, 2025

PARIS, March 31, 2025--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), will publish a business update and host a videoconference on Wednesday, April 9, 2025 after the market closes.

Business Wire last month

ALCAR.PA
+0.02%
CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment

PARIS, March 27, 2025--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), announces the implementation of a flexible equity financing line with IRIS Capital Investment ("IRIS"), for a maximum of 9,000,000 shares (i.e., approximately 15% of its current share capital), over a 24-month period.

Business Wire last month

ALCAR.PA
+0.02%
CARMAT: Aeson® total artificial heart highlighted as a very promising solution for heart failure patients with pulmonary hypertension in The Journal of Heart and Lung Transplantation

PARIS, February 17, 2025--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces the publication in The Journal of Heart and Lung Transplantation, of an article on the performance of Aeson® total artificial heart in treating heart failure patients with pulmonary hypertension.

Business Wire 2 months ago

ALCAR.PA
+0.02%
CARMAT Achieves the Milestone of 100 Implants of Its Aeson® Total Artificial Heart

PARIS, February 10, 2025--CARMAT achieves the milestone of 100 implants of its Aeson® total artificial heart

Business Wire 2 months ago

ALCAR.PA
+0.02%
CARMAT: 2025 Financial Calendar

PARIS, January 29, 2025--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces its indicative financial calendar for 2025.

Business Wire 3 months ago

ALCAR.PA
+0.02%
CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the 1st Half of 2025

PARIS, January 13, 2025--CARMAT announces its participation in several scientific and investor conferences during the 1st half of 2025

Business Wire 3 months ago

ALCAR.PA
+0.02%
CARMAT Delivers a Solid FY 2024 with 42 Implants of Its Aeson® Artificial Heart and Anticipates Continued Strong Momentum in 2025

PARIS, January 08, 2025--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), announces its 2024 annual sales2 and provides an update on its development outlook.

Business Wire 3 months ago

ALCAR.PA
+0.02%
CARMAT optimizes its financial structure by buying-back, for a symbolic sum of one euro, 2 million shares from Matra-Défense (Airbus group) which will be allocated to the repayment of its financial debt

PARIS, December 23, 2024--CARMAT optimizes its financial structure by buying-back, for a symbolic sum of one euro, 2 million shares from Matra-Défense (Airbus group)

Business Wire 4 months ago

ALCAR.PA
+0.02%
Successful first "Aeson® European User Meeting", marking an important step in the deployment of CARMAT's artificial heart

PARIS, November 26, 2024--Successful first "Aeson® European User Meeting", marking an important step in the deployment of CARMAT's artificial heart

Business Wire 5 months ago

ALCAR.PA
+0.02%
CARMAT's Aeson® Artificial Heart Is Gradually Becoming a Reference Solution for Bridge to Transplant in Europe

PARIS, November 13, 2024--CARMAT's Aeson® artificial heart is gradually becoming a reference solution for bridge to transplant in Europe.

Business Wire 5 months ago

ALCAR.PA
+0.02%
Half of Enrolments Targeted in the EFICAS Study Reached by CARMAT

PARIS, September 12, 2024--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces that it has reached half of the enrolments targeted in the EFICAS study.

Business Wire 7 months ago

ALCAR.PA
+0.02%
CARMAT Publishes Its 2024 Half-Year Results and Provides an Update on Its Outlook

PARIS, September 06, 2024--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces its results for the first half ending June 30, 20242, and provides an update on its progress and prospects.

Business Wire 7 months ago

ALCAR.PA
+0.02%
CARMAT Announces Its Participation in Several Scientific and Investor Conferences during the 2nd Half of 2024

PARIS, September 03, 2024--CARMAT announces its participation in several scientific and investor conferences during the 2nd half of 2024

Business Wire 7 months ago

ALCAR.PA
+0.02%
CARMAT accelerates its sales momentum and reiterates its confidence in its development outlook

PARIS, July 09, 2024--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), provides an update on its achievements over the first half of 2024 and reiterates its confidence in its development outlook.

Business Wire 9 months ago

CKMTF

Performance Overview

Return	ALCAR.PA	CAC 40 (^FCHI)
YTD	-26.13%	+4.28%
1-Year	-76.11%	-3.75%
3-Year	-92.91%	+22.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Carmat SA (ALCAR.PA)

CARMAT: Availability of the 2024 Universal Registration Document

CARMAT Announces Its 2024 Annual Results

FDA conditionally approves second cohort of Carmat’s artificial heart study

CARMAT Receives FDA Conditional Approval to Initiate the Second Cohort of the EFS Study in the United States

CARMAT Delivers Q1 2025 Results in Line With Its Objectives

CARMAT - Publication in the JACC(1): Heart Failure of the Initial Clinical Experience with Aeson® Total Artificial Heart in Cardiogenic Shock Patients Initially Placed on Extracorporeal Life Support

CARMAT to Provide a Business Update and Host a Videoconference on April 9, 2025

CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment

CARMAT: Aeson® total artificial heart highlighted as a very promising solution for heart failure patients with pulmonary hypertension in The Journal of Heart and Lung Transplantation

CARMAT Achieves the Milestone of 100 Implants of Its Aeson® Total Artificial Heart

CARMAT: 2025 Financial Calendar

CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the 1st Half of 2025

CARMAT Delivers a Solid FY 2024 with 42 Implants of Its Aeson® Artificial Heart and Anticipates Continued Strong Momentum in 2025

CARMAT optimizes its financial structure by buying-back, for a symbolic sum of one euro, 2 million shares from Matra-Défense (Airbus group) which will be allocated to the repayment of its financial debt

Successful first "Aeson® European User Meeting", marking an important step in the deployment of CARMAT's artificial heart

CARMAT's Aeson® Artificial Heart Is Gradually Becoming a Reference Solution for Bridge to Transplant in Europe

Half of Enrolments Targeted in the EFICAS Study Reached by CARMAT

CARMAT Publishes Its 2024 Half-Year Results and Provides an Update on Its Outlook

CARMAT Announces Its Participation in Several Scientific and Investor Conferences during the 2nd Half of 2024

CARMAT accelerates its sales momentum and reiterates its confidence in its development outlook

Performance Overview